Initial reports have also documented remarkable clinical responses in patients with advanced chronic lymphocytic leukemia (CLL) or lymphoma after therapy with CD19-specific CAR-T cells [21-25]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.